Qiagen (QGEN) Cash & Equivalents (2009 - 2026)

Qiagen has disclosed Cash & Equivalents across 18 years of filings, most recently posting $646.3 million for Q1 2026.

• Cash & Equivalents for Q1 2026 came in at $646.3 million, up 1.18% year-over-year; the trailing twelve-month figure through Mar 2026 was $646.3 million (up 1.18% YoY), and the FY2025 annual result was $839.0 million, up 26.44% from the prior year.
• Cash & Equivalents came in at $646.3 million for Q1 2026 at Qiagen, down from $839.0 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $1.4 billion in Q3 2025 to a low of $359.2 million in Q1 2023.
• The 5-year median for Cash & Equivalents is $665.8 million (2023), against an average of $741.4 million.
• Across the five-year window, Cash & Equivalents soared 105.91% in 2022 and tumbled 54.39% in 2023, its largest moves.
• Qiagen's Cash & Equivalents stood at $1.3 billion in 2022, then tumbled by 47.46% to $668.1 million in 2023, then retreated by 0.68% to $663.6 million in 2024, then rose by 26.44% to $839.0 million in 2025, then fell by 22.97% to $646.3 million in 2026.
• The last three Cash & Equivalents figures came in at $646.3 million (Q1 2026), $839.0 million (Q4 2025), and $1.4 billion (Q3 2025), per Business Quant data.